Usually, influenza epidemics and outbreaks pose threats for public health around the world. The global rapid influenza diagnostic tests (RIDT) market is anticipated to witness considerable expansion during the coming period. At present, these tests are being preferred compared to the traditional techniques on account of their capability to recognize the occurrence of viral antigens of type A and B of influenza. These tests detect the viral antigens within the respiratory specimens and offer the results in qualitative format. The short time period required by rapid influenza diagnostic tests to present outcomes makes it a preferred option, thus driving the growth of the global rapid influenza diagnostic tests (RIDT) market.
Further, the need for rapid influenza diagnostic tests market is expected to be fueled by the rising requirement for cost-effective & rapid diagnostic tests, growing initiatives by government to curb influenza outbursts, technological improvements in immunoassay methods & manufacture of diagnostic kits, and escalating elderly population. Moreover, the growing attentiveness, easy obtainability of test kits along with the swelling healthcare spending in budding economies are other few factors projected to boost the market expansion. Also, accessibility to elevated aid for influenza diagnostic tests is expected to boost the market expansion during the forecast period. Nonetheless, dearth of skilled experts might obstruct the growth of the global rapid influenza diagnostic tests (RIDT) market.
At present, the novel coronavirus outbreak has created havoc across the globe thus demanding more tests to be conducted to identify infected patients. Thus this situation is likely to bring up new opportunities for market players in the near future.
To cite, Quidel Corporation, a supplier of rapid diagnostic testing solutions, molecular diagnostic systems, and cellular-based virology assays, declared that it has obtained Emergency Use Authorization from the US FDA to commercialize its rapid point-of-care test, Sofia® 2 SARS Antigen FIA, to be utilized with the Sofia 2 Fluorescent Immunoassay Analyzer for the quicker recognition of SARS-CoV-2 in nasopharyngeal or nasal samples from patients meeting the criteria of CDC criteria for supposed COVID-19 infection.
Get Research Report Sample PDF for more Industry Insights – https://www.zionmarketresearch.com/requestbrochure/rapid-influenza-diagnostic-tests-market